PO.CL01.12 · 临床研究
pelareorep治疗的早期乳腺癌样本的成像质谱流式细胞术揭示发育中的三级淋巴结构
Imaging mass cytometry of pelareorep treated early breast cancer samples reveals developing tertiary lymphoid structures
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
AWARE-1是一项机会窗研究,评估溶瘤病毒(OV)pelareorep在早期乳腺癌患者中的效果。本分析聚焦于队列2(n=8),由HR+ HER2-患者组成,这些患者在第1、2、8、9天接受pelareorep;第1-21天接受来曲唑;第3天接受阿替利珠单抗。分别在治疗前、第3天和第21天采集活检组织。使用靶向多种免疫细胞亚群的成像质谱流式细胞术(IMC)抗体组合对组织进行染色,以表征肿瘤免疫微环境(TiME)随时间的变化,以及部分受试者中随后发育的三级淋巴结构(TLS)。无监督PhenoGraph聚类识别出18种不同的表型,包括辅助性T细胞(Th)、活化辅助性T细胞(ATh)、细胞毒性T细胞(CTC)、B细胞(BC)、分化B细胞(DBC)和树突状细胞(DC)。从筛选期到第21天样本(p=0.04)以及从第3天到第21天样本(p=0.04),CTC显著增加。使用细胞邻域分析对这些细胞类型及其相互作用方式进行进一步分析,该分析可识别整个样本中某些细胞类型的常见排列。细胞邻域分析产生了一个有趣的邻域簇,包含CTC、DC、TH、BC、DBC和M2巨噬细胞——定义为TLS邻域。TLS邻域的可视化显示T细胞和B细胞组织的进展阶段,在筛选期T细胞和B细胞大体上呈弥散且无结构状态,到第21天则浓缩成BC区带——即被CTC、TH和ATH细胞包围的BC聚集体。对构成TLS邻域的细胞应用基于成对置换的相互作用分析,以验证显著的生物学组织。在第21天,BC-TH、DBC-BC和DBC-DBC相互作用比筛选期显著更可能发生。其他值得注意的相互作用包括肿瘤-ATH、肿瘤-CTC、肿瘤-DC、CTC-ATH和CTC-CTC相互作用,它们在手术时显著增加。本研究是首个此类研究,识别并空间验证了经OV pelareorep治疗的早期乳腺癌患者TiME中独特的细胞-细胞相互作用作为发育中的TLS,突显了与TLS形成相关的协调性TiME重组和新颖的细胞-细胞相互作用动态。
查看英文原文 English abstract
AWARE-1 is a window-of-opportunity study evaluating the effects of the oncolytic virus (OV) pelareorep in early-stage breast cancer patients. This analysis focuses on Cohort 2 (n = 8), consisting of HR+ HER2- patients who received pelareorep on days 1, 2, 8, 9; letrozole on days 1-21; and atezolizumab on day 3. Biopsies were collected pre-treatment, on day 3, and on day 21. Tissue was stained using an imaging mass cytometry (IMC) antibody cocktail targeting a variety of immune cell subsets to characterize changes over time in the tumor immune microenvironment (TiME) and the subsequent development of tertiary lymphoid structures (TLS) in select subjects. Unsupervised PhenoGraph clustering identified 18 distinct phenotypes, including T helper (Th), activated T helper (ATh), cytotoxic T cells (CTC), B cells (BC), differentiated B cells (DBC), and dendritic cells (DC). CTC's were significantly increased from screening to day 21 samples (p = 0.04) and from day 3 to day 21 samples (p = 0.04). Further analysis of these cell types and how they interact is performed using cellular neighborhood analysis, which identifies common arrangements of certain cell types throughout the samples. Cellular neighborhood analysis yielded an interesting neighborhood cluster comprising CTC, DC, TH, BC, DBC, and M2 Mac cells - defined as the TLS neighborhood. Visualization of the TLS neighborhood showed progressing stages of T cell and B cell organization, with T cells and B cells being largely diffuse and unstructured at screening and concentrating into zones of BC - BC aggregates surrounded by CTC, TH, and ATH cells at day 21. Pairwise permutation-based interaction analysis was applied to the cells comprising the TLS neighborhood to validate significant biological organization. At day 21 BC - TH, DBC - BC, and DBC - DBC interactions were significantly more likely to occur than at screening. Other interactions of note were between tumor - ATH, tumor - CTC, tumor - DC, CTC - ATH, and CTC - CTC interactions were significantly increased at surgery. This study is the first of its kind to identify and spatially validate the unique cell-cell interactions in the TiME of early breast cancer patients treated with the OV pelareorep as developing TLS's, highlighting coordinated TiME reorganization and novel cell-cell interaction dynamics associated with TLS formation.
利益披露 Disclosure
J. P. Olea,
NIH/National Cancer Center ).
Roche (RHBY) Stock.
Anneal (AMRX) Stock.
Sarepta (SRPT) Stock.
H. Dadrastoussi,
NIH/National Cancer Center ).
K. Wu,
NIH ).
H. Wu, None..
P. Zarand, None..
C. Villa Celi, None.
J. S. Carew,
Majestic Therapeutics Other, Support.
S. T. Nawrocki,
Majestic Therapeutics Other, Support.
X. Chen, None.
R. Trauger,
Oncolytics Biotech, Inc. Employment.
T. C. Heineman,
Oncolytics Biotech, Inc. Employment.
K. R. Kelly,
Oncolytics Biotech Inc. ).
National Cancer Center Core Grants ).
Ming Hsieh Institute at the University of Southern California ).
Merck ).
Whittier Initiative at the University of Southern California–Translational Research ).
Takeda ).
Janssen Gift.
Ipsen Biopharmaceuticals Gift.
AstraZeneca Gift.
Karyopharm Therapeutics Gift.
Servier Pharmaceuticals Gift.
Gilead Sciences Inc. Gift.
Seagen Inc. Gift.
Eli Lilly and Company Gift.
Bristol-Myers Squibb Gift.
GSK Gift.
AbbVie Gift.
ACI Clinical Gift.
Denovo Biopharma Gift.
Incyte Pharmaceuticals Gift.